{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:54:56Z","timestamp":1793040896560,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40272-025-00727-0","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:37:40Z","timestamp":1762501060000},"page":"15-29","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances in Pharmacotherapy for Congenital Hyperinsulinism"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0550-4665","authenticated-orcid":false,"given":"Nuria","family":"Gonz\u00e1lez-Llorens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3559-6479","authenticated-orcid":false,"given":"Daphne","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3721-5043","authenticated-orcid":false,"given":"Mar\u00eda Clemente","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6374-5884","authenticated-orcid":false,"given":"Huseyin","family":"Demirbilek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4280-7470","authenticated-orcid":false,"given":"Indraneel","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4402-8297","authenticated-orcid":false,"given":"Pratik","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"727_CR1","first-page":"1","volume":"17","author":"D Lapidus","year":"2024","unstructured":"Lapidus D, De Le\u00f3n DD, Thornton PS, Hood D, Breit J, Raskin J, et al. The birth prevalence of congenital hyperinsulinism: a narrative review of the epidemiology of a rare disease. Horm Res Paediatr. 2024;17:1\u20138.","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"727_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228417","volume":"15","author":"D Yau","year":"2020","unstructured":"Yau D, Laver TW, Dastamani A, Senniappan S, Houghton JAL, Shaikh G, et al. Using referral rates for genetic testing to determine the incidence of a rare disease: the minimal incidence of congenital hyperinsulinism in the UK is 1 in 28,389. PLoS ONE. 2020;15(2):e0228417.","journal-title":"PLoS ONE"},{"issue":"4","key":"727_CR3","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/MOP.0000000000000645","volume":"30","author":"ME Vajravelu","year":"2018","unstructured":"Vajravelu ME, De Le\u00f3n DD. Genetic characteristics of patients with congenital hyperinsulinism. Curr Opin Pediatr. 2018;30(4):568\u201375.","journal-title":"Curr Opin Pediatr"},{"issue":"4","key":"727_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s11154-020-09548-7","volume":"21","author":"M G\u03cbemes","year":"2020","unstructured":"G\u03cbemes M, Rahman SA, Kapoor RR, Flanagan S, Houghton JAL, Misra S, et al. Hyperinsulinemic hypoglycemia in children and adolescents: recent advances in understanding of pathophysiology and management. Rev Endocr Metab Disord. 2020;21(4):577\u201397.","journal-title":"Rev Endocr Metab Disord"},{"key":"727_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2013.00060","volume":"4","author":"HB Avatapalle","year":"2013","unstructured":"Avatapalle HB, Banerjee I, Shah S, Pryce M, Nicholson J, Rigby L, et al. Abnormal neurodevelopmental outcomes are common in children with transient congenital hyperinsulinism. Front Endocrinol (Lausanne). 2013;4:60.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"727_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/cen.14152","volume":"92","author":"C Worth","year":"2020","unstructured":"Worth C, Yau D, Salomon Estebanez M, O\u2019Shea E, Cosgrove K, Dunne M, et al. Complexities in the medical management of hypoglycaemia due to congenital hyperinsulinism. Clin Endocrinol (Oxf). 2020;92(5):387\u201395.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"727_CR7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/archdischild-2015-308336","volume":"101","author":"M G\u00fcemes","year":"2016","unstructured":"G\u00fcemes M, Rahman SA, Hussain K. What is a normal blood glucose? Arch Dis Child. 2016;101(6):569\u201374.","journal-title":"Arch Dis Child"},{"key":"727_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1231043","volume":"14","author":"MG Shaikh","year":"2023","unstructured":"Shaikh MG, Lucas-Herald AK, Dastamani A, Salomon Estebanez M, Senniappan S, Abid N, et al. Standardised practices in the networked management of congenital hyperinsulinism: a UK national collaborative consensus. Front Endocrinol (Lausanne). 2023;14:1231043.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"727_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000531766","volume":"97","author":"DD De Leon","year":"2023","unstructured":"De Leon DD, Arnoux JB, Banerjee I, Bergada I, Bhatti T, Conwell LS, et al. International guidelines for the diagnosis and management of hyperinsulinism. Horm Res Paediatr. 2023;97(3):279\u201398.","journal-title":"Horm Res Paediatr"},{"key":"727_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.873254","volume":"13","author":"TI Hewat","year":"2022","unstructured":"Hewat TI, Johnson MB, Flanagan SE. Congenital hyperinsulinism: current laboratory-based approaches to the genetic diagnosis of a heterogeneous disease. Front Endocrinol (Lausanne). 2022;13:873254.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"727_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1530\/EJE-12-0673","volume":"168","author":"RR Kapoor","year":"2013","unstructured":"Kapoor RR, Flanagan SE, Arya VB, Shield JP, Ellard S, Hussain K. Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism. Eur J Endocrinol. 2013;168(4):557\u201364.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"727_CR12","first-page":"817","volume":"39","author":"AR Larsen","year":"2024","unstructured":"Larsen AR, Brusgaard K, Christesen HT, Detlefsen S. Genotype-histotype-phenotype correlations in hyperinsulinemic hypoglycemia. Histol Histopathol. 2024;39(7):817\u201344.","journal-title":"Histol Histopathol"},{"issue":"5","key":"727_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/jmg.2008.064337","volume":"46","author":"C James","year":"2009","unstructured":"James C, Kapoor RR, Ismail D, Hussain K. The genetic basis of congenital hyperinsulinism. J Med Genet. 2009;46(5):289\u201399.","journal-title":"J Med Genet"},{"issue":"4","key":"727_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.beem.2018.05.014","volume":"32","author":"S Galcheva","year":"2018","unstructured":"Galcheva S, Al-Khawaga S, Hussain K. Diagnosis and management of hyperinsulinaemic hypoglycaemia. Best Pract Res Clin Endocrinol Metab. 2018;32(4):551\u201373.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"727_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1159\/000526442","volume":"95","author":"PS Thornton","year":"2022","unstructured":"Thornton PS, Stanley CA, De Leon DD. Congenital hyperinsulinism: an historical perspective. Horm Res Paediatr. 2022;95(6):631\u20137.","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"727_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2967\/jnumed.121.262327","volume":"63","author":"M Boss","year":"2022","unstructured":"Boss M, Rottenburger C, Brenner W, Blankenstein O, Prasad V, Prasad S, et al. 68Ga-NODAGA-Exendin-4 PET\/CT improves the detection of focal congenital hyperinsulinism. J Nucl Med. 2022;63(2):310\u20135.","journal-title":"J Nucl Med"},{"issue":"1","key":"727_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13052-020-00894-5","volume":"46","author":"A Casertano","year":"2020","unstructured":"Casertano A, De Matteis A, Mozzillo E, Rosanio FM, Buono P, Fattorusso V, et al. Diagnosis of congenital hyperinsulinism can occur not only in infancy but also in later age: a new flow chart from a single center experience. Ital J Pediatr. 2020;46(1):131.","journal-title":"Ital J Pediatr"},{"issue":"9","key":"727_CR18","first-page":"69","volume":"30","author":"H Demirbilek","year":"2017","unstructured":"Demirbilek H, Hussain K. Congenital hyperinsulinism: diagnosis and treatment update. J Clin Res Pediatr Endocrinol. 2017;30(9):69\u201387.","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"727_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00156","author":"A Helleskov","year":"2017","unstructured":"Helleskov A, Melikyan M, Globa E, Shcherderkina I, Poertner F, Larsen AM, et al. Both low blood glucose and insufficient treatment confer risk of neurodevelopmental impairment in congenital hyperinsulinism: a multinational cohort study. Front Endocrinol (Lausanne). 2017. https:\/\/doi.org\/10.3389\/fendo.2017.00156.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"727_CR20","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00431-013-2053-0","volume":"172","author":"H Al-Otaibi","year":"2013","unstructured":"Al-Otaibi H, Senniappan S, Alam S, Hussain K. Biochemical studies in patients with hyperinsulinaemic hypoglycaemia. Eur J Pediatr. 2013;172(11):1435\u201340.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"727_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jpeds.2015.03.057","volume":"167","author":"PS Thornton","year":"2015","unstructured":"Thornton PS, Stanley CA, De Leon DD, Harris D, Haymond MW, Hussain K, et al. Recommendations from the pediatric endocrine society for evaluation and management of persistent hypoglycemia in neonates, infants, and children. J Pediatr. 2015;167(2):238\u201345.","journal-title":"J Pediatr"},{"issue":"8","key":"727_CR22","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1172\/JCI25495","volume":"115","author":"FM Ashcroft","year":"2005","unstructured":"Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Investig. 2005;115(8):2047\u201358.","journal-title":"J Clin Investig"},{"issue":"2","key":"727_CR23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1749-6632.1968.tb19045.x","volume":"150","author":"J Black","year":"1968","unstructured":"Black J. Diazoxide and the treatment of hypoglycemia: an historical review. Ann N Y Acad Sci. 1968;150(2):194\u2013203.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"727_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/cen.14991","volume":"100","author":"AYL Ng","year":"2024","unstructured":"Ng AYL, Agrawal P, Vijayan R, Arya VB, Kapoor RR, Shah P. Low-dose diazoxide therapy in hyperinsulinaemic hypoglycaemia. Clin Endocrinol (Oxf). 2024;100(2):140\u20132.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"727_CR25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/cen.14987","volume":"100","author":"N Malhotra","year":"2024","unstructured":"Malhotra N, Yau D, Cunjamalay A, Gunasekara B, Athanasakopoulou S, Gilbert C, et al. Low-dose diazoxide is safe and effective in infants with transient hyperinsulinism. Clin Endocrinol (Oxf). 2024;100(2):132\u20137.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"727_CR26","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000478696","volume":"88","author":"R Kizu","year":"2017","unstructured":"Kizu R, Nishimura K, Sato R, Kosaki K, Tanaka T, Tanigawara Y, et al. Population pharmacokinetics of diazoxide in children with hyperinsulinemic hypoglycemia. Horm Res Paediatr. 2017;88(5):316\u201323.","journal-title":"Horm Res Paediatr"},{"issue":"6","key":"727_CR27","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/cen.14096","volume":"91","author":"SC Chen","year":"2019","unstructured":"Chen SC, Dastamani A, Pintus D, Yau D, Aftab S, Bath L, et al. Diazoxide-induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: recommendations from a multicentre study in the United Kingdom. Clin Endocrinol (Oxf). 2019;91(6):770\u20135.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"727_CR28","doi-asserted-by":"publisher","first-page":"F306","DOI":"10.1136\/archdischild-2020-319057","volume":"106","author":"LA Prado","year":"2021","unstructured":"Prado LA, Castro M, Weisz DE, Jain A, Belik J. Necrotising enterocolitis in newborns receiving diazoxide. Arch Dis Child Fetal Neonatal Ed. 2021;106(3):F306\u201310.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"2","key":"727_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246463","volume":"16","author":"X Chen","year":"2021","unstructured":"Chen X, Feng L, Yao H, Yang L, Qin Y. Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: a systematic review and meta-analysis. PLoS ONE. 2021;16(2):e0246463.","journal-title":"PLoS ONE"},{"issue":"12","key":"727_CR30","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1210\/jc.2018-01613","volume":"103","author":"A Herrera","year":"2018","unstructured":"Herrera A, Vajravelu ME, De Le\u00f3n DD. Prevalence of adverse events in children with congenital hyperinsulinism treated with diazoxide. J Clin Endocrinol Metab. 2018;103(12):4365\u201372.","journal-title":"J Clin Endocrinol Metab"},{"key":"727_CR31","first-page":"13","volume":"27","author":"ME van Albada","year":"2022","unstructured":"van Albada ME, Mohnike K, Dunne MJ, Banerjee I, Betz SF. Somatostatin receptors in congenital hyperinsulinism: biology to bedside. Front Endocrinol (Lausanne). 2022;27:13.","journal-title":"Front Endocrinol (Lausanne)."},{"key":"727_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/2042018820965068","author":"B Haris","year":"2020","unstructured":"Haris B, Saraswathi S, Hussain K. Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia. Ther Adv Endocrinol Metab. 2020. https:\/\/doi.org\/10.1177\/2042018820965068.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"9","key":"727_CR33","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1507\/endocrj.EJ17-0024","volume":"64","author":"Y Hosokawa","year":"2017","unstructured":"Hosokawa Y, Kawakita R, Yokoya S, Ogata T, Ozono K, Arisaka O, et al. Efficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registry. Endocr J. 2017;64(9):867\u201380.","journal-title":"Endocr J"},{"issue":"1","key":"727_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13023-015-0367-x","volume":"10","author":"A Welters","year":"2015","unstructured":"Welters A, Lerch C, Kummer S, Marquard J, Salgin B, Mayatepek E, et al. Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers. Orphanet J Rare Dis. 2015;10(1):150.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"727_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/pds.4144","volume":"26","author":"AW McMahon","year":"2017","unstructured":"McMahon AW, Wharton GT, Thornton P, De Leon DD. Octreotide use and safety in infants with hyperinsulinism. Pharmacoepidemiol Drug Saf. 2017;26(1):26\u201331.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"727_CR36","doi-asserted-by":"publisher","first-page":"278","DOI":"10.6065\/apem.2142010.005","volume":"26","author":"CF Mooij","year":"2021","unstructured":"Mooij CF, Tacke CE, Van Albada ME, Barthlen W, Bikker H, Mohnike K, et al. Pasireotide treatment for severe congenital hyper-insulinism due to a homozygous ABCC8 mutation. Ann Pediatr Endocrinol Metab. 2021;26(4):278\u201383.","journal-title":"Ann Pediatr Endocrinol Metab."},{"key":"727_CR37","doi-asserted-by":"crossref","unstructured":"Hawkes CP, Lado JJ, Givler S, De Leon DD. The effect of continuous intravenous glucagon on glucose requirements in infants with congenital hyperinsulinism. In: JIMD reports. Springer; 2019. p. 45\u201350.","DOI":"10.1007\/8904_2018_140"},{"key":"727_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00441","volume":"11","author":"M Salomon-Estebanez","year":"2020","unstructured":"Salomon-Estebanez M, Yau D, Dunne MJ, Worth C, Birch S, Walewski JL, et al. Efficacy of dose-titrated glucagon infusions in the management of congenital hyperinsulinism: a case series. Front Endocrinol (Lausanne). 2020;11:441.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"727_CR39","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1152\/physrev.00025.2016","volume":"97","author":"TD M\u00fcller","year":"2017","unstructured":"M\u00fcller TD, Finan B, Clemmensen C, DiMarchi RD, Tsch\u00f6p MH. The new biology and pharmacology of glucagon. Physiol Rev. 2017;97(2):721\u201366.","journal-title":"Physiol Rev"},{"issue":"1","key":"727_CR40","first-page":"19","volume":"2019","author":"D Yau","year":"2019","unstructured":"Yau D, Salomon-Estebanez M, Chinoy A, Grainger J, Craigie RJ, Padidela R, et al. Central venous catheter-associated thrombosis in children with congenital hyperinsulinism. Endocrinol Diabetes Metab Case Rep. 2019;2019(1):19\u201332.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"1","key":"727_CR41","first-page":"59","volume":"70","author":"K Mohnike","year":"2008","unstructured":"Mohnike K, Blankenstein O, Pfuetzner A, P\u00f6tzsch S, Schober E, Steiner S, et al. Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon. Horm Res. 2008;70(1):59\u201364.","journal-title":"Horm Res"},{"issue":"2","key":"727_CR42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2165\/00003088-199630020-00002","volume":"30","author":"T Salvatore","year":"1996","unstructured":"Salvatore T, Giugliano D. Pharmacokinetic-pharmacodynamic relationships of acarbose. Clin Pharmacokinet. 1996;30(2):94\u2013106.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"727_CR43","first-page":"822","volume":"102","author":"M G\u00fcemes","year":"2017","unstructured":"G\u00fcemes M, Shah P, Silvera S, Morgan K, Gilbert C, Hinchey L, et al. Assessment of nifedipine therapy in hyperinsulinemic hypoglycemia due to mutations in the abcc8 gene. J Clin Endocrinol Metab. 2017;102(3):822\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"727_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/19336950.2020.1761171","volume":"14","author":"MC De Mingo Alemany","year":"2020","unstructured":"De Mingo Alemany MC, Mifsud Grau L, Moreno Maci\u00e1n F, Ferrer Lorente B, Le\u00f3n CS. A de novo CACNA1D missense mutation in a patient with congenital hyperinsulinism, primary hyperaldosteronism and hypotonia. Channels. 2020;14(1):175\u201380.","journal-title":"Channels"},{"issue":"1","key":"727_CR45","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-017-0621-5","volume":"12","author":"I Banerjee","year":"2017","unstructured":"Banerjee I, De Leon D, Dunne MJ. Extreme caution on the use of sirolimus for the congenital hyperinsulinism in infancy patient. Orphanet J Rare Dis. 2017;12(1):70.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"727_CR46","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1210\/js.2018-00417","volume":"3","author":"G Maria","year":"2019","unstructured":"Maria G, Antonia D, Michael A, Kate M, Sian E, Sarah FE, et al. Sirolimus: efficacy and complications in children with hyperinsulinemic hypoglycemia: a 5-year follow-up study. J Endocr Soc. 2019;3(4):699\u2013713.","journal-title":"J Endocr Soc"},{"issue":"4","key":"727_CR47","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1210\/clinem\/dgad648","volume":"109","author":"PS Thornton","year":"2024","unstructured":"Thornton PS, De Leon DD, Empting S, Zangen D, Kendall DM, Birch S, et al. Dasiglucagon for the treatment of congenital hyperinsulinism: a randomized phase 3 trial in infants and children. J Clin Endocrinol Metab. 2024;109(4):1071\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"727_CR48","first-page":"11","volume":"27","author":"J Sikimic","year":"2020","unstructured":"Sikimic J, Hoffmeister T, Gresch A, Kaiser J, Barthlen W, Wolke C, et al. Possible new strategies for the treatment of congenital hyperinsulinism. Front Endocrinol (Lausanne). 2020;27:11.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"9","key":"727_CR49","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40265-021-01531-z","volume":"81","author":"HA Blair","year":"2021","unstructured":"Blair HA. Dasiglucagon: first approval. Drugs. 2021;81(9):1115\u201320.","journal-title":"Drugs"},{"issue":"3","key":"727_CR50","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2337\/dc17-1402","volume":"41","author":"U H\u00f6velmann","year":"2018","unstructured":"H\u00f6velmann U, Bysted BV, Mouritzen U, Macchi F, Lamers D, Kronshage B, et al. Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog. Diabetes Care. 2018;41(3):531\u20137.","journal-title":"Diabetes Care"},{"issue":"7","key":"727_CR51","doi-asserted-by":"publisher","first-page":"e1548","DOI":"10.1210\/clinem\/dgad741","volume":"109","author":"G Tamaro","year":"2024","unstructured":"Tamaro G, Solidoro S, Tornese G. Dasiglucagon: a new hope for diazoxide-unresponsive, nonfocal congenital hyperinsulinism? J Clin Endocrinol Metab. 2024;109(7):e1548\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"727_CR52","doi-asserted-by":"publisher","first-page":"e2674","DOI":"10.1210\/clinem\/dgae818","volume":"110","author":"DD De Leon","year":"2024","unstructured":"De Leon DD, Banerjee I, Kummer S, Birch S, B\u00f8ge E, Ivkovic J, et al. Dasiglucagon in children with congenital hyperinsulinism up to 1 year of age: results from a randomized clinical trial. J Clin Endocrinol Metab. 2024;110:e2674\u201381.","journal-title":"J Clin Endocrinol Metab"},{"key":"727_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100611","author":"H Demirbilek","year":"2025","unstructured":"Demirbilek H, Melikyan M, Iotova V, Galcheva S, Ozbek MN, Dastamani A, et al. Global, multi-center, repeat-dose, phase 2 study of RZ358 (ersodetug), an insulin receptor antibody, for congenital hyperinsulinism. Med. 2025. https:\/\/doi.org\/10.1016\/j.medj.2025.100611.","journal-title":"Med"},{"issue":"1","key":"727_CR54","doi-asserted-by":"publisher","first-page":"16765","DOI":"10.1038\/s41598-022-21251-y","volume":"12","author":"YH Heo","year":"2022","unstructured":"Heo YH, Kim JK, Lee JS, Lee SH, Shin SH, Choi IY, et al. A novel glucagon analog with an extended half-life, HM15136, normalizes glucose levels in rodent models of congenital hyperinsulinism. Sci Rep. 2022;12(1):16765.","journal-title":"Sci Rep"},{"key":"727_CR55","first-page":"1","volume":"95","author":"Wonjung Shin JKGLAMAIBADKMEOHC& DDDLe\u00f3n","year":"2022","unstructured":"Wonjung Shin JKGLAMAIBADKMEOHC& DDDLe\u00f3n. An ongoing phase 2 study of HM15136, a novel long-acting glucagon analogue, in subjects with congenital hyperinsulinism (ACHIEVE, Outline Protocol). ESPE Abstracts. 2022;95:1\u201388.","journal-title":"ESPE Abstracts."},{"issue":"10","key":"727_CR56","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.2337\/db12-0166","volume":"61","author":"AC Calabria","year":"2012","unstructured":"Calabria AC, Li C, Gallagher PR, Stanley CA, De Le\u00f3n DD. GLP-1 receptor antagonist exendin-(9\u201339) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel. Diabetes. 2012;61(10):2585\u201391.","journal-title":"Diabetes"},{"issue":"6","key":"727_CR57","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.2337\/dc21-2009","volume":"45","author":"D Stefanovski","year":"2022","unstructured":"Stefanovski D, Vajravelu ME, Givler S, De Leon DD. Exendin-(9\u201339) effects on glucose and insulin in children with congenital hyperinsulinism during fasting and during a meal and a protein challenge. Diabetes Care. 2022;45(6):1381\u201390.","journal-title":"Diabetes Care"},{"key":"727_CR58","doi-asserted-by":"crossref","unstructured":"Juliana CA, Chai J, Arroyo P, Rico-Bautista E, Betz SF, De Le\u00f3n DD. A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism. J Biol Chem. 2023;299(6).","DOI":"10.1016\/j.jbc.2023.104816"},{"issue":"4","key":"727_CR59","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1056\/NEJMc2312807","volume":"390","author":"H Dauleh","year":"2024","unstructured":"Dauleh H, Amin R, Pasha M, Hussain K. Adjuvant alpelisib therapy for congenital hyperinsulinism. N Engl J Med. 2024;390(4):379\u201380.","journal-title":"N Engl J Med"},{"key":"727_CR60","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luaf099","author":"K Alburshad","year":"2025","unstructured":"Alburshad K, Amin R, Dauleh H, Ibrahim M, Hussain K. Alpelisib therapy in 2 patients with congenital hyperinsulinism. JCEM Case Rep. 2025. https:\/\/doi.org\/10.1210\/jcemcr\/luaf099.","journal-title":"JCEM Case Rep"},{"key":"727_CR61","doi-asserted-by":"crossref","unstructured":"Elsheikh A, Driggers CM, Truong HH, Yang Z, Allen J, Henriksen NM, et al. AI-based discovery and cryoEM structural elucidation of a KATP channel pharmacochaperone. Elife [Internet]. 2025;13. https:\/\/elifesciences.org\/articles\/103159.","DOI":"10.7554\/eLife.103159"},{"key":"727_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2016.00008","volume":"7","author":"I Banerjee","year":"2016","unstructured":"Banerjee I, Forsythe L, Skae M, Avatapalle HB, Rigby L, Bowden LE, et al. Feeding problems are persistent in children with severe congenital hyperinsulinism. Front Endocrinol (Lausanne). 2016;7:8.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"727_CR63","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000491105","volume":"91","author":"ME Vajravelu","year":"2019","unstructured":"Vajravelu ME, Congdon M, Mitteer L, Koh J, Givler S, Shults J, et al. Continuous intragastric dextrose: a therapeutic option for refractory hypoglycemia in congenital hyperinsulinism. Horm Res Paediatr. 2019;91(1):62\u20138.","journal-title":"Horm Res Paediatr"},{"issue":"4","key":"727_CR64","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/MOP.0000000000001243","volume":"35","author":"E Rosenfeld","year":"2023","unstructured":"Rosenfeld E, De Le\u00f3n DD. Bridging the gaps: recent advances in diagnosis, care, and outcomes in congenital hyperinsulinism. Curr Opin Pediatr. 2023;35(4):486\u201393.","journal-title":"Curr Opin Pediatr"},{"key":"727_CR65","first-page":"13","volume":"19","author":"SH Auckburally","year":"2022","unstructured":"Auckburally SH, Worth C, Salomon-Estebanez M, Nicholson J, Harper S, Nutter PW, et al. Families\u2019 experiences of continuous glucose monitoring in the management of congenital hyperinsulinism: a thematic analysis. Front Endocrinol (Lausanne). 2022;19:13.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"1","key":"727_CR66","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jpedsurg.2018.10.030","volume":"54","author":"NS Adzick","year":"2019","unstructured":"Adzick NS, De Leon DD, States LJ, Lord K, Bhatti TR, Becker SA, et al. Surgical treatment of congenital hyperinsulinism: results from 500 pancreatectomies in neonates and children. J Pediatr Surg. 2019;54(1):27\u201332.","journal-title":"J Pediatr Surg"},{"issue":"5","key":"727_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098054","volume":"9","author":"VB Arya","year":"2014","unstructured":"Arya VB, Senniappan S, Demirbilek H, Alam S, Flanagan SE, Ellard S, et al. Pancreatic endocrine and exocrine function in children following near-total pancreatectomy for diffuse congenital hyperinsulinism. PLoS ONE. 2014;9(5):e98054.","journal-title":"PLoS ONE"}],"updated-by":[{"DOI":"10.1007\/s40272-025-00729-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000}}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00727-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00727-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00727-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:02:37Z","timestamp":1770048157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00727-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["727"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00727-0","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"18 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the organization name Children\u2019s Hyperinsulinism Charity\nin the Acknowledgements\nand Declarations sections.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40272-025-00729-y","URL":"https:\/\/doi.org\/10.1007\/s40272-025-00729-y","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MC participated as principal investigator and NGL as sub-investigator in the clinical trials (phase II and phase III) for ersodetug funded by Rezolute. HD participated as principal investigator in the clinical trials (phase II and phase III) for ersodetug funded by Rezolute. He is an associate editor for Frontiers in Endocrinology. He is involved with the patient charities Congenital Hyperinsulinism Charity, Turkiye, and Congenital Hyperinsulinism International. IB received grant funding for clinical trials by Zealand Pharma, Rezolute Pharma, Crinetics Pharma and Hanmi Pharma. IB was the Chair of the NIHR Paediatric Endocrinology Clinical Studies Group and is a co-chair of the UK Children\u2019s Hospital Alliance Research Oversight Group. He is an associate editor for Frontiers in Endocrinology. IB is involved with the patient charities Children\u2019s Hyperinsulinism Charity, UK, and Congenital Hyperinsulinism International. PS is the founder of Congenital Hyperinsulinism India Association (CHIA), and is involved with the patient charities Children\u2019s Hyperinsulinism Charity, UK (as Patron), and Congenital Hyperinsulinism International. He has also been involved with clinical trials by Zealand Pharma and Rezolute Pharma. He is a guest associate editor for Frontiers in Endocrinology. DY participated as principal investigator in the phase III clinical trial funded by Rezolute. She is involved with the patient charity Congenital Hyperinsulinism International.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"NGL and PS designed, developed and wrote the manuscript. IB, HD, MC, and DY wrote the manuscript. NGL created Fig.\n                      \n                      . All authors have read and approved the final version of the manuscript, and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}